This announcement is a separate document:
シンバイオ製薬：造血幹細胞移植後におけるサイトメガロウイルス感染症患者を対象とした注射剤ブリンシドフォビルによる第2a相臨床試験においてFPI（第１例目）を達成
SymBio Pharmaceuticals: FPI (the first case) was achieved in the phase 2a clinical trial of the injection brincidofovir targeting patients with cytomegalovirus infection after hematopoietic stem cell transplantation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.